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Abstract: Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid (PUFA) with 20 carbon atoms and 5 carbon-carbon 
double bonds. Mammalian cells cannot synthesize long chain PUFAs such as EPA de novo, and, thus, the most effective way to enrich 
cells in EPA is by dietary intake of fish oils. EPA supplementation causes an increase in its concentration in plasma lipids and in cell 
membrane phospholipids. Many beneficial effects of EPA supplementation have been noted, including (1) the potential to sensitize 
cancerous tumors towards chemotherapy, (2) the promotion of cardiovascular health, and (3) the alleviation of some mental disorders, 
but results from clinical trials have sometimes been disparate. In this study, we report the use of mass spectrometry to investigate the 
autoxidation of EPA, thereby demonstrating the formation of a variety of oxidized products. The oxidative stress of the patient may 
affect the response to EPA and may, in part, explain divergent results from clinical trials.
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Introduction
Eicosapentaenoic acid (EPA) is an omega-3 polyun-
saturated fatty acid (PUFA) with 20 carbon atoms and 
5 carbon-carbon double bonds and is designated as 
20:5 (ω-3) (Fig. 1). Mammalian cells cannot synthe-
size long chain PUFAs de novo, although EPA can be 
synthesized from the essential fatty acid, α-linolenic 
acid (ALA), 18:3 (ω-3), but conversion is minimal.1 
The most effective way to enrich cells in EPA is by 
dietary intake of fish oils.2
There is an active interest in understanding the 
effects of dietary supplementation of EPA as evidenced 
by the number of trials exploring the use of this sub-
stance in improving human health. For instance, with 
respect to cancer, marine-derived lipids, such as EPA, 
have the potential to sensitize tumors toward chemo-
therapy and enhance the cytotoxicity of certain anti-
cancer drugs while preserving (or possibly) enhancing 
the integrity of non-tumor tissue.3 PUFAs are known 
to increase the presence of reactive oxygen species in 
cancer cells and may contribute to improving neutro-
phil function thus enhancing the action of the innate 
immune system.4 Further studies, however, are nec-
essary to understand the mechanism whereby PUFAs 
selectively sensitize tumor cells but not normal tis-
sue toward chemotherapeutic drugs. Certain cancers 
also lead to muscle loss or wasting (known as cancer 
cachexia), with patients exhibiting reduced levels of 
plasma omega-3 lipids that continue to decline over 
the course of the disease.5 In this case, ongoing stud-
ies and trials indicate that fish oil supplements are 
beneficial.6
There is also evidence from clinical trials and 
randomized controlled trials that omega-3 fatty acid 
supplementation decreases cardiovascular events 
and the risk of cardiac death.7 The exact mechanisms 
whereby omega-3 fatty acids contribute to decreasing 
cardiovascular events are not clear, although effects 
such as plaque stabilization,8 lipid profile altera-
tion,9 triglyceride reduction,10 blood pressure reduc-
tion,11 inhibition of inflammation,12 or  reduction in 
 arrhythmia have been suggested.13 While the general 
trend might be that these oils are beneficial, other 
data indicate either insufficient evidence14,15 or even 
an increased risk of cardiac death among patients 
advised to take oily fish.16 The reasons for these 
discrepancies are not clear, although potential con-
cerns have been raised with regard to the quality 
and rigor of some trials and the fact that in some 
studies, patients were already receiving cardiopro-
tective agents, for example, statins, such that further 
supplementation with an omega-3 fatty acid may not 
have had an impact.17,18
The effects of EPA supplementation have also 
been investigated in patients with schizophrenia and 
other mental health-related disorders. Certain lipids 
are integral to the brain and significant membrane 
abnormalities have been identified in the brains of 
schizophrenic patients.19 The enzyme phospholi-
pase A (PLA2), which releases arachidonic acid, 
20:4 (ω-6) from membrane phospholipids is thought 
to be overactive in schizophrenic brains. EPA supple-
mentation may be beneficial since EPA may compete 
with arachidonic acid for incorporation into mem-
brane phospholipids and thus inhibit the enzyme.20 
While a pilot study indicated that EPA is beneficial 
in the  treatment of schizophrenia,21 a more recent 
meta-analysis of EPA data does not indicate a favor-
able role in schizophrenia and related psychologi-
cal  disorders.22 However, there may be confounding 
effects in previous trials since a differential response 
to EPA may occur depending on the history of phar-
macological intervention, and an overall conclusion 
may not be available as yet.
The role of EPA may be controversial, but the 
indications are that EPA supplementation has, in 
some cases, shown promise in ameliorating or pre-
venting several conditions. Therefore, it becomes 
important to understand the mechanisms of action. 
However, before biological mechanisms can be fully 
interpreted, it is essential to appreciate the chemical 
nature of EPA and the transformations that EPA can 
undergo. EPA shows reactivity toward oxygen, and is 
known to autoxidize readily. In this study, we inves-
tigated the autoxidation of EPA by mass spectrom-
etry and report a number of oxidized products and 
their possible assignments. In this regard, we have 
reviewed some of the schemes involving the autoxi-
dation of EPA.
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Figure 1. Structure of eicosapentaenoic acid (ePA), 20:5 (ω-3). 
note: Positions 7, 10, 13, and 16 indicate bis-allylic (methylenic) 
 hydrogen locations.
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Methods
Materials
The sodium salt of cis-5,8,11,14,17- eicosapentaenoic 
acid (EPA, $99% purity) was purchased from Sigma 
Aldrich (St. Louis, MO). The sodium salt of EPA 
was stored prior to use as received (under nitrogen) 
in the solid form at −80 °C. Henceforth, the sodium 
salt of EPA is referred to as “EPA.” Several portions 
of EPA (0.5 mg) in glass vials (approximately 2 cm 
in diameter and 6 cm in height) were allowed to oxi-
dize in air at ambient temperature (22.2 °C–25.4 °C) 
over 2 to 4 days under conditions of ∼12 hours light 
and ∼12 hours dark. At the time of analysis, EPA was 
dissolved in molecular grade water (1 mL) from Cell-
gro (distilled; deionized; DNAse, RNAse, and protease 
tested). While the sodium salt of EPA has limited solu-
bility, we found that the amounts used (i.e. 0.5 mg/mL 
water) were fully soluble. Stock solutions were further 
diluted with molecular grade water before introduc-
tion to the mass spectrometer. When analyzing fresh 
EPA (i.e. when recording control mass spectra of the 
sodium salt of EPA), all manipulations were performed 
under nitrogen gas. In this regard, EPA was handled 
under nitrogen gas and dissolved in molecular grade 
water that had previously been purged with nitrogen.
Mass spectrometry
Native EPA and air-oxidized EPA samples were pre-
pared as indicated above and dissolved in molecu-
lar grade water (0.17 mM). Samples were analyzed 
using an Applied Biosystems MDS SCIEX API 2000 
 instrument (AB SCIEX, Framingham, MA). The mass 
spectrometer was operated in negative ion mode with a 
mass range of m/z 250 to 600 amu, using a declustering 
potential (DP) of −60.0 V, a focusing potential (FP) of 
−400.0 V, and an entrance potential (EP) of −100.0 V. 
Nitrogen was used as both the sheath gas and the aux-
iliary gas. Data acquisition and analysis were per-
formed using Analyst software, version 1.4. Samples 
were introduced via syringe injection at a flow rate of 
10.00 µL/min. Spectra (100 cycles) were accumulated 
over a 5-minute period.
Results
Mass spectral analysis of autoxidized ePA
The sodium salt of EPA, a white powder, oxidizes 
readily in air as evidenced by a change in color to 
a yellow solid within a short period of time. When 
this process was monitored by mass spectrometry, 
several new species were observed within 0 to 4 days 
of exposure to air (Fig. 2). Mass spectral analysis of 
fresh native EPA gives rise to a main peak at 300.9 m/z 
(exact mass of acidic form of EPA = 302.2 amu), 
which corresponds to the deprotonated anion, that is, 
(exact mass-H)/z. The main peak at 300.9 m/z dis-
plays the correct isotopic pattern, giving two shoul-
ders at 302.1 m/z (exact mass = 303.2 amu) and 
303.1 m/z (exact mass = 304.2 amu) (Fig. 2, blue 
spectrum). While care was taken to exclude oxygen, 
some small peaks mainly centered at 317.0 m/z and 
333.1 m/z were also observed, indicating that either 
the EPA contains some oxidized product, or else a 
small amount of oxidation occurred during the han-
dling process. However, mass spectrometric analysis 
of several samples of fresh native EPA consistently 
revealed small amounts of oxidized product.
Oxidation over several days revealed the forma-
tion of species with higher masses (Fig.2 A–C). For 
example, after 2 days of air oxidation, small clus-
ters of ions centered at 317.0, 333.1, 348.9, and 
365.0 m/z were observed to increase with a cor-
responding decrease of native EPA at 300.9 m/z 
(Fig. 2B, red spectrum). After 4 days of air oxidation, 
new species clustered at 380.7 m/z and 396.7 m/z 
appeared, accompanied by a decrease of parent EPA 
(300.9 m/z) together with a decrease in ions centered 
at 317.0 and 331.1 m/z (Fig. 2B, green spectrum). 
Notably, the average difference in mass between the 
peaks of greatest intensity in each cluster group is 
15.97 ± 0.07 amu, corresponding to mass of an oxy-
gen atom. Thus, the groups of ions centered at 317.0, 
333.1, 348.9, 365.0, 380.7, and 396.7 m/z represent, 
respectively, the addition of 1, 2, 3, 4, 5, and 6 oxy-
gen atoms to native EPA. The facts that (1) the rela-
tive intensities of these peaks changed with time and 
(2) higher masses were observed after longer expo-
sures to air indicate that their presence is real and not 
an artifact of the mass spectrometric process. In some 
cases, where the peaks representing oxidized EPA ions 
are larger, it is possible to discern an isotopic pattern 
(which is also clearly apparent in non-oxidized EPA 
at 300.9 m/z).
While each cluster group can be ascribed to an 
ion having 1 to 6 additional oxygen atoms compared 
with the parent ion, it also appears that species within 
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Figure 2. Air oxidation of ePA leads to products of increased mass. Mass spectra of (A) native ePA (blue), and ePA oxidized in air for 2 and 4 days 
(red and green spectra, respectively). Native ePA gives a peak at 300.9 m/z (amu). (B) Magnified view of the same mass range as (a), with the mass of 
the dominant peak in each cluster group identified as the addition of 1, 2, 3, 4, 5, or 6 oxygen [O] atoms to EPA. (c) Magnified view of the 325–365 m/z 
range, highlighting the separation of peaks in each cluster of ions by 2.05 ± 0.04 (amu), representing the loss or gain of 2 hydrogen atoms. Peaks 
may also represent ions formed upon loss of water as, for instance, indicated for a species of mass 365.0 m/z losing h2O to yield a species of mass 
346.8 m/z.
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each cluster group are separated by 2.05 ± 0.04 amu 
(Fig. 2C). This difference represents either an incre-
mental gain or loss of 2 hydrogen atoms. While autox-
idation pathways are covered in more detail below, 
possible mechanisms could include ring-opening of 
cyclic peroxides resulting in the formation of hydroxy 
compounds (i.e. gain of 2 hydrogen atoms) or, con-
versely, keto formation from an alcohol (i.e. loss of 
2 hydrogen atoms). Loss of water from compounds 
could also result (i.e. loss of 18 amu).
The species that result from autoxidation of 
EPA appeared and disappeared at different rates, 
as shown by plots of peak intensity versus time 
(Fig. 3). The peak intensity of the parent EPA ion 
decreased over 4 days (Fig. 3A). Several species in 
the cluster groups with 1 or 2 oxygen atom additions 
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Figure 3. Variation of peak intensity with time. Peak intensities are monitored over time (0–4 days) to indicate the rate at which ions appear or disappear. 
(A) Parent ePA ion at 300.9 m/z and the cluster group of ions with (B) 1 oxygen [O] atom addition, (c) 2 oxygen atoms, (D) 3 oxygen atoms, (e) 4 oxygen 
atoms, (F) 5 oxygen atoms, and (G) 6 oxygen atoms.
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 (designated as EPA + 1[O] and EPA + 2[O] in Fig. 3B 
and C,  respectively) also disappeared over 4 days. 
 Conversely, some species (indicated by peaks at 312.9, 
326.8, 328.8, and 330.8 m/z) were formed during this 
time, perhaps from precursors that are being reduced 
in intensity. The clusters of peaks representing the 
addition of 3, 4, 5, and 6 oxygen atoms all increased 
with time (Fig. 3D–G). Notably, the higher-mass spe-
cies (e.g. EPA + 5[O] and EPA + 6[O]) only started to 
appear after 2 days, indicating that the higher-mass 
oxidized species are formed from the lower-mass oxi-
dized species and that oxygen addition is a sequential 
process.
Comparison of the total intensity of peaks in the 
290 to 450 m/z region shows that ∼30% of the total 
intensity is lost after 2 days and is further reduced 
after 4 days (∼50% that of the original spectrum). 
While a comparison of total intensity may not pro-
vide a consistent method of comparing spectra, the 
indication is that there is an overall loss of intensity. 
Although the loss of intensity is not fully understood, 
it is possible that some of the species formed are not 
detected by the mass spectrometric process or else 
occur at masses outside the region shown. Although 
oxidized EPA appears soluble giving rise to clear, 
 yellow solutions, it is also possible that the solubility 
of some of the oxidized species is limited.
Discussion
In this study, we sought to identify the types of prod-
ucts formed when the sodium salt of EPA is autoxi-
dized in air at ambient temperature. To the best of 
our knowledge, this represents the first study in which 
the autoxidation process was allowed to occur in 
the solid phase in the presence of air and light but 
in the absence of any solvent or exogenously-added 
 peroxide/free-radical initiating species. Previous 
mass spectrometric studies of in vitro oxidized EPA 
products have involved the addition of free-radical 
initiating compounds to EPA dissolved in organic 
solvents.23,24 Gas chromatography coupled with mass 
spectrometry (GC-MS) provides a sensitive method 
for characterizing products of PUFA oxidation, but 
often requires the derivatization of products prior to 
analysis.25 To prevent additional modification that 
may occur during the GC-MS process, an alternative 
method may be used that utilizes liquid chromatogra-
phy to separate compounds before being introduced 
to the ion source and characterized by tandem mass 
spectrometry (LC-MS/MS). These methods have pre-
viously been successfully applied to profiling oxidized 
lipids, for instance, in plasma and urine samples.26,27 
In the current study, we applied electrospray ioniza-
tion mass spectrometry to the direct observation of 
oxidized EPA species.
Our results indicated that species containing up to 
6 oxygen atoms result from air oxidation (Fig. 2). In 
addition to these species, we also observed ions that 
were separated by 2.05 ± 0.04 amu from the main 
peak of each cluster group (and, in some cases, by 
18 amu between peaks of different cluster groups). In 
order to make potential assignments, it is necessary 
to consider schemes of oxygen addition and autoxida-
tion, as described below.
Basic products of ePA autoxidation
Unsaturated fatty acids are susceptible to oxidation 
due to the fact that the formation of a free radical on 
a carbon atom located between 2 carbon-carbon dou-
ble bonds (otherwise known as a bis-allylic position) 
is remarkably stable.28 Thus, it is relatively easy to 
remove a hydrogen atom from EPA to produce a radi-
cal that can interact with an oxygen molecule. EPA 
has four bis-allylic moieties, centered at C-7, C-10, 
C-13, and C-16 (Fig. 1).
Scheme 1 illustrates a mechanism of EPA oxygen-
ation, which is based on the mechanism of arachi-
donic acid oxygenation.23 EPA is similar in structure 
to arachidonic acid in that it has a 20-carbon back-
bone but, unlike arachidonic acid, EPA has 5 carbon-
carbon double bonds (versus 4 in arachidonic acid) 
and is an omega-3 fatty acid (rather than arachidonic 
acid which is an omega-6 fatty acid). Due to their 
similarities in structure, similar mechanisms may 
apply to oxygenation of both EPA and arachidonic 
acid. Lipid oxidation can be initiated by certain tran-
sition metals, such as iron, but physiologically, lipid 
oxidation may occur enzymatically in a selective 
manner. For instance, oxygenation of arachidonic 
acid by the cyclooxygenase enzymes (COX-1 and 
COX-2) initiates the cascade leading to prostaglan-
din (PG)  formation. Oxygenation by COX occurs 
when arachidonic acid lies in the cyclooxygenase 
channel with the C-13 position adjacent to tyrosine-
385 in the polypeptide backbone. The catalytic pro-
cess involves tyrosine cation radical production, 
eicosapentaenoic acid sodium salt autoxidation
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Physiologically, EPA oxidation is expected to 
occur enzymatically but, under situations of oxida-
tive stress, nonenzymatic routes may also occur in 
living systems.30 EPA is prone to peroxidation and 
can be oxidized nonenzymatically, often resulting in 
prostaglandin-like substances, called isoprostanes.24 
When only lipid radicals and oxygen are involved, 
the process is known as “autoxidation,” but simi-
lar mechanisms may be involved in both enzyme-
catalyzed lipid oxidation and autoxidation. Thus, 
Scheme 1 illustrates a mechanism of EPA oxygen-
ation with initial hydrogen abstraction occurring at 
the C-13 position. Rearrangement leads to radical 
formation at the C-11 position with subsequent radi-
cal trapping of oxygen, followed by the formation 
of a 5-membered endoperoxide ring, cyclization, 
further rearrangement and a second oxygenation at 
C-15. Reduction results in the production of F3 iso-
prostane (also known as PGF3α).
An important difference between enzyme-
 catalyzed lipid oxygenation and autoxidation is that 
enzyme- directed oxygenations are stereospecific. 
 Autoxidation of arachidonic acid is well elucidated 
and can occur at different bis-allylic positions.31 In 
this regard, autoxidation of EPA can, in principle, be 
initiated at any of the C-7, C-10, C-13, or C-16 sites.23 
Novel oxidation products of EPA have previously 
been identified using mass spectrometric techniques 
including Ag+ coordination ionspray and atmospheric 
pressure chemical ionization mass spectrometry.23 
Importantly, these oxidation products were observed 
both in vitro and in vivo.23 Scheme 2 illustrates the 
collection of hydroperoxyeicosapentaenoic acid 
(HpEPE) and hydroxyeicosapentaenoic (HEPE) iso-
mers that could form following initiation at the 4 dif-
ferent bis-allylic positions. According to Scheme 2, 
the peaks observed at 317.0 and 333.1 m/z (Fig. 2) 
represent the addition of 1 and 2 oxygen atoms to EPA, 
respectively, and can potentially be ascribed to HEPE 
and HpEPE isomers of EPA (exact masses = 318.2 
amu and 334.2 amu, respectively).
Monocyclic and serial cyclic  
peroxide formation
Monocyclic and serial cyclic peroxide products of 
EPA have previously been investigated.23 Scheme 3A 
represents the type of monocyclic (1,2-dioxolane) 
and serial cyclic peroxides that can, in principle, form 
H
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COOH
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O
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15 
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2H•, –[O]  
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scheme 1. Mechanism of ePA oxygenation. Oxygenation of ePA (1) is 
initiated by hydrogen abstraction of the C-13 position (2), allowing oxy-
gen to add at C-11 (3), followed by endoperoxide formation (4), further 
cyclization (5) and the addition of a second oxygen to produce a bicyclic 
endoperoxide (6), which can be reduced to a F3 isoprostane (7). For sim-
plicity, the stereochemistry of the structures is not shown.
which is  responsible for stereoselective abstraction 
of the 13-pro-S hydrogen from the C-13 position and 
thus initiating oxygenation.29 EPA can readily replace 
arachidonic acid in the lipid bilayer and act as a sub-
strate for the COX enzymes.
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scheme 2. hydrogen abstraction at C-7, C-10, C-13, and C-16 yields a wide variety of hydroperoxyeicosapentaenoic acid (hpePe) and hydroxyeicosa-
pentaenoic acid (hePe) products. hydrogen abstraction of ePA (1) at C-7, leads to the 5- and 9-series of hePe and hpePe products (8–11); at C-10 
results in the 8- and 12-series of hePe and hpePe products (12–15); at C-13 yields the 11- and 15-series of hePe and hpePe products (16–19), and at 
C-16 leads to the 14- and 18-series of hePe and hpePe products (20–23).
when initial hydrogen abstraction occurs at C-13, fol-
lowed by rearrangement to yield a carbon radical at 
C-11 to allow initial oxygen addition, that is, (1) to (3) 
in Scheme 1. In this particular example, EPA can poten-
tially gain 4 oxygen atoms (monocyclic peroxide), or 
else peroxidation can go further yielding a structure 
with 6 oxygen atoms (serial cyclic peroxide).
The position of initial hydrogen abstraction and 
subsequent location of the carbon radical (with respect 
to its proximity to carbon-carbon double bonds) 
eicosapentaenoic acid sodium salt autoxidation
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 determine the extent of peroxidation and dioxolane 
formation. For instance, structures are possible with 
only 2 oxygen atom additions (i.e. when oxygen first 
adds to a carbon radical on either C-5 or C-18) or 
up to 8 oxygen atom additions (i.e. when oxygen 
first adds to C-9 or C-14 radicals). For example, 
hydrogen abstraction at C-7 leading to a radical on 
C-9 allows addition of 4, 6, or 8 oxygen atoms, as 
shown in Scheme 3B. When hydrogen abstraction at 
C-7 instead leads to radical formation on C-5, only 
2 oxygen atom additions are possible with the result 
that 5-HpEPE is formed.
In summary, depending on the position of car-
bon radical formation, it is possible to form HpEPEs 
(2 oxygen atoms; exact mass = 334.21 amu), 
monocyclic peroxides (4 oxygen atoms; exact 
mass = 366.20 amu) and serial cyclic peroxides con-
taining 2 dioxolane rings (6 oxygen atoms, exact 
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5
scheme 3. Oxygenation of ePA yields monocyclic and serial cyclic peroxides. (A) Following hydrogen abstraction from C-13 of ePA (1) and subsequent 
endoperoxide radical formation (4), oxygen addition can occur at the C-8 position leading to the formation of a monocyclic peroxide (24), with possible 
further oxygen addition at C-5 yielding a serial cyclic peroxide (25). (B) hydrogen abstraction from C-7 leading to a radical on C-9 allows addition of 
4 oxygen atoms (26), 6 oxygen atoms (27) or 8 oxygen atoms (28).
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mass = 398.19 amu) or 3  dioxolane rings (8 oxygen 
atoms, exact mass = 430.18 amu). As these rearrange-
ments and additions occur, EPA, which is not initially 
conjugated, becomes a partially conjugated system. 
Upon reduction of the hydroperoxyl moiety to yield a 
hydroxyl group, it is possible to form the correspond-
ing dioxolane structures with 1, 3, 5, and 7 oxygen 
atoms (exact masses = 318.22, 350.21, 382.20, and 
414.19 amu, respectively). The mass spectra did not 
yield evidence of a structure corresponding to 8  oxygen 
atom additions (exact mass = 430.18 amu), but it was 
possible to observe a species with m/z = 413.0, poten-
tially indicative of a structure with 7 oxygen atoms 
(exact mass = 414.19 amu; data not shown).
hydrogen abstraction at multiple  
bis-allylic carbon positions
Hydrogen abstraction that occurs at multiple bis-
allylic carbon positions in EPA can result in struc-
tures that contain multiple hydroxyl and/or peroxyl 
adducts. This is illustrated in Scheme 4 for 5-HpEPE 
that results from initial hydrogen abstraction at C-7. 
Subsequent removal of a hydrogen atom from C-10 
results in diHpEPE, which has another bis-allylic 
position at C-16 that can undergo further hydrogen 
abstraction. The resulting structures include triH-
pEPE and triHEPE. The triHEPE compounds are 
also known as resolvins and have been found to have 
anti-inflammatory properties.32–34 Notably, in human 
endothelial cells, aspirin therapy causes COX-2 to 
switch its catalytic activity from forming prostanoids 
to producing specific HEPEs and novel trihydroxy-
containing resolvins.32 In particular, 5,12,18-triHEPE, 
also known as RvE1, has been associated with having 
potent anti-inflammatory and analgesic properties.35
Products of enzymatic oxygenation 
versus autoxidation
EPA can readily replace arachidonic acid in the lipid 
bilayer and act as a substrate for the COX enzymes. 
When arachidonic acid is the COX substrate, the 
prostaglandin (PG-2) series of products is formed, 
where the number 2 corresponds to the number of 
carbon-carbon double bonds in the product.  However, 
when COX metabolizes EPA, the PG-3 series is 
formed, with products containing 3 double bonds.36 
Eicosanoids that are produced with arachidonic acid 
as the initiating substrate are often associated with 
proatherogenic and proinflammatory properties. In 
contrast, eicosanoids derived from EPA are associ-
ated with less biological activity and therefore have 
less of an impact on the process of inflammation 
or  proliferation.37 For instance, oxidized EPA sig-
nificantly inhibited human neutrophil and monocyte 
adhesion to endothelial cells by preventing expression 
of the endothelial adhesion receptor via a mechanism 
involving activation of the peroxisome proliferator-
activated receptor α (PPARα) and subsequent inhibi-
tion of NF-κB.38,39
Scheme 5 indicates that following bicyclic 
endoperoxide (PGG3) formation, reduction occurs 
forming PGH3, which can then be converted to sev-
eral different types of eicosanoids, depending on the 
available enzymes. In the presence of PGE synthase 
(PGES) or PGDS, the products PGE3 and PGD3 can 
form. Interestingly, it has previously been noted that 
both PGE2 and PGD2 (the analogous products of 
arachidonic acid metabolism) can form independent 
of COX.30 In general, although the products that 
result from enzymatic catalysis and autoxidation 
may be similar, there may be important distinctions 
in cis-trans orientations of side chains with respect 
to the prostane ring, with non-enzymatic routes 
favoring racemic mixtures. However, for COX-inde-
pendent formation of PGE2 and PGD2, the products 
were found to be identical to COX-derived PGE2 
and PGD2.
30 Thus, it may be possible for PGE3 and 
PGD3 to result from autoxidation. PGA3 and PGJ3 
(not shown) result from dehydration of PGE3 and 
PGD3, respectively. Interestingly, it has previously 
been found that incubation of EPA with free-radical 
generating compounds in ethanol leads to the iden-
tification by mass spectrometry of PGA3 and PGJ3-
like products (termed A3/J3 isoprostanes).
24 Thus, 
products similar to PGA3 and PGJ3 may also result 
during autoxidation.
Further products requiring enzymatic catalysis 
include PGI3 (catalyzed by prostacyclin synthase), 
which is likely unstable and converts to 6-keto-
PGF3α (as PGI2 converts readily to 6-keto-PGF2α). 
 Importantly, the arachidonate-derived PGI2 is a potent 
vasodilator and inhibitor of platelet aggregation. 
Platelet-derived thromboxane synthase would con-
vert PGH3 to thromboxane B3, the stable hydrolysis 
product of TxA3. Notably, the arachidonate-derived 
eicosapentaenoic acid sodium salt autoxidation
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TxA2 has properties completely opposed to PGI2, in 
that it is a potent inducer of platelet aggregation and 
vasoconstrictor. A diet rich in EPA has been found to 
lead to both PGI3 and TxA3 production and a con-
comitant reduction in thrombogenic TxA2.
40
Possible assignments of ePA 
autoxidation products
Possible assignments of EPA autoxidation products 
observed by mass spectrometry are listed in Table 1. 
Compounds, outlined in Schemes 1–5, that result from 
COOH
OOH
(8) 5-HpEPE 
Exact mass = 334.21 
5
(9) 5-HEPE 
Exact mass = 318.22 
COOH
OH
5
COOH
OOH
OOH
(30) 5,12-diHpEPE 
Exact mass = 366.20 
COOH
OOH
(29)
COOH
OOH
OOH
(33)
COOH
OOH
OOH OOH
(34) 5,12,18-triHpEPE 
Exact mass = 398.19 
COOH
OH
OOH OOH
(36) 5-hydroxy-12,18-diHpEPE 
Exact mass = 382.20 
COOH
OH
OH OOH
(35) 5,12-dihydroxy-18-HpEPE 
Exact mass = 366.20 
COOH
OH
OH OH
(37) 5,12,18-triHEPE 
Exact mass = 350.21 
H
O2 , H 
H
O2, H 
[O]
COOH
OH
OOH
(31) 5-hydroxy-12-HpEPE 
Exact mass = 350.21 
COOH
OH
OH
(32) 5,12-diHEPE 
Exact mass = 334.21 
[O]
[O]
10
16
scheme 4. hydrogen abstraction at multiple bis-allylic carbon positions yields a mix of hydroxy and hydroperoxy products. Initial hydrogen abstraction at 
C-7 results in 5-hpePe (8), which can be reduced to 5-hePe (9), or alternately, be subject to removal of a hydrogen atom at C-10 to form dihpePe (30). 
Further hydrogen abstraction at the bis-allylic position at C-16 results in the formation of structures that include trihpePe (34) and trihePe (37), as well 
as other structures (and isomers) containing hydroxyl and peroxyl groups.
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scheme 5. ePA metabolism by cyclooxygenase and other enzymes. Following bicyclic endoperoxide (Pgg3) formation (6), reduction occurs forming 
Pgh3 (38), which can then be converted to several types of eicosanoids, in the presence of different enzymes. Pge synthase (PgeS) or PgDS converts 
Pgh3 to Pge3 (39) and PgD3 (40), respectively. PgA3 (43) and PgJ3 (not shown) result from dehydration of Pge3 (39) and PgD3 (40), respectively. 
Prostacyclin synthase converts Pgh3 to PgI3 (41), which is likely unstable and dehydrates to 6-keto-PgF3α (44). Platelet-derived thromboxane synthase 
converts Pgh3 to thromboxane B3 (42), the stable hydrolysis product of TxA3.
non-enzymatic oxidation of EPA include HEPEs, 
HpEPEs, monocyclic peroxides, bicyclic endoperox-
ides, serial cyclic peroxides, and potentially a series 
of compounds with several hydroxyl or peroxyl moi-
eties are included as possible  products. Table 1 shows 
that several isomers are possible for a single peak (and 
not all possible isomers are considered). Other species 
were also noted that are incrementally 2.05 ± 0.04 amu 
lower or higher in mass than the main ions in each 
cluster group  representing a gain of 1–6 oxygen atoms 
(Fig. 2). This mass is consistent with 2  hydrogen 
atoms. Possible mechanisms that involve a gain of 
eicosapentaenoic acid sodium salt autoxidation
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Table 1. examples of possible assignments of mass spectrometric peaks.
Observed mass 
(anion) m/z (amu)
Formula possible assignments of the neutral form exact mass 
(amu)
300.9 C20h30O2 ePA (1) 302.22
 
317.0
 
C20h30O3
1 oxygen addition 
hePe (scheme 2) (9), (11), (13), (15), (17), (19), (21), (23)
 
318.22
 
330.8 
333.1
 
C20h28O4 
C20h30O4
2 oxygen additions 
PgA3 (PgJ3) (scheme 5) (43) 
hpePe (scheme 2) (8), (10), (12), (14), (16), (18), (20), (22) 
dihePe (scheme 4) (32)
 
332.20 
334.21
 
348.9
 
C20h30O5
3 oxygen additions 
hydroxy-hpePe (scheme 4) (31)  
trihePe (scheme 4) (37) 
Pgh3 (scheme 5) (38), Pge3 (39), PgD3 (40)
 
350.21
351.0 C20h32O5 F3 isoprostane (scheme 1) (7) 352.22
 
365.0
 
C20h30O6
4 oxygen additions 
Bicyclic endoperoxide, Pgg3 (scheme 1) (6) 
dihpePe (scheme 4) (30) 
dihydroxy-hpePe (scheme 4) (35) 
Monocyclic peroxide (scheme 3) (24), (26)
 
366.20
 
380.7
 
C20h30O7
5 oxygen additions 
hydroxy-dihpePe (scheme 4) (36)
 
382.20
 
396.7
 
C20h30O8
6 oxygen additions 
Serial cyclic peroxide (scheme 3) (25), (27) 
trihpePe (scheme 4) (34)
 
398.19
2 hydrogen atoms include ring-opening of cyclic 
peroxides resulting in hydroxyl compounds or, 
 conversely, keto formation from an alcohol involves 
a loss of 2 hydrogen atoms. Dehydration could also 
contribute, as this would result in a loss of 18 amu.
conclusion
Lipid peroxidation can be a function of physiological 
as well as pathophysiological processes.  Dissecting 
which processes are the result of normal function 
versus those that are the result of disease and aging 
might be difficult. Given that enzymatic processes 
might also be accompanied by lipid peroxidation by 
non-enzymatic routes, it may be possible that, given 
their oxidative stress level, patients may differ in their 
response to EPA and thus give rise to divergent results 
in clinical trials. Given the propensity of EPA to react 
with oxygen in the absence of exogenously added free-
radical initiators, it is important that patient populations 
receive the same quality of EPA to ensure that results 
from clinical trials are comparable. However, it may 
be possible that differential responses to EPA may still 
occur given the oxidative stress level of the patient.
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